PDE4B-Selective Inhibitors for Burn Injury Muscle Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skeletal muscle cachexia resulting from burn injuries are inadequate, as existing PDE4 inhibitors cause adverse effects such as nausea and emesis, and there is a need for targeted therapies to address muscle loss and inflammation.
Innovation Solution
Administering a PDE4B-selective inhibitor to treat skeletal muscle cachexia, which specifically targets PDE4B, the predominant isoform involved in muscle cachexia, thereby reducing muscle proteolysis and inflammation without the adverse effects associated with PDE4D inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PDE4 inhibitors are administered to treat skeletal muscle cachexia, then muscle proteolysis is reduced, but adverse effects such as nausea and emesis occur due to PDE4D inhibition
Solution Approach 1:
The patent segments the PDE4 enzyme family into distinct isoforms (PDE4A, PDE4B, PDE4C, PDE4D) and develops inhibitors that selectively target only PDE4B, which is responsible for muscle proteolysis, while leaving PDE4D (associated with nausea and emesis) unaffected. This selective inhibition resolves the contradiction by achieving therapeutic effectiveness without adverse effects.
Solution Approach 2:
The patent applies local quality by creating inhibitors with specific molecular characteristics that confer selectivity for PDE4B over other PDE4 isoforms. The inhibitors possess structural features (such as specific substitutions at positions R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100) that enable selective binding to PDE4B, thereby achieving localized therapeutic action at the target isoform level.
2Reliability
If PDE4 inhibitors are used to treat skeletal muscle cachexia, then muscle loss is reduced, but the treatment lacks specificity and causes off-target effects
Solution Approach 1:
The patent divides the PDE4 enzyme family into functionally distinct isoforms and develops inhibitors that specifically target PDE4B, the isoform responsible for regulating muscle proteolysis. This segmentation approach eliminates off-target effects on other PDE4 isoforms while maintaining therapeutic efficacy.
Solution Approach 2:
The patent optimizes the molecular parameters of the inhibitors (including substitutions at multiple positions R1-R100) to achieve high selectivity for PDE4B. By carefully adjusting these chemical parameters, the inhibitors display enhanced binding affinity for PDE4B while minimizing interaction with other PDE4 isoforms, thereby resolving the specificity issue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of PDE4B-selective inhibitors effectively reduces muscle proteolysis and promotes muscle recovery in burn-injured subjects, preventing muscle loss and weight gain retardation, while avoiding the adverse effects of non-selective PDE4 inhibition.
Implementation Method 1
inhibitors of PDE4, a major regulator of intracellular cAMP concentrations, can attenuate muscle atrophy
Data Source
AI summary
A method of treating skeletal muscle cachexia and inflammation associated with burn injury in a subject in need thereof is provided, the method including administering to the subject an effective amount of a phosphodiesterase-4B (PED4B)-selective inhibitor.